US · ASBPW
Aspire Biopharma Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Humacao, NY 10013
- Website
- aspirebiolabs.com
Price · as of 2024-12-31
$0.02
Market cap 6.21M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Aspire Biopharma Holdings, Inc.'s (ASBPW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.02
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ASBPW | Aspire Biopharma Holdings… | $0.02 | 6.21M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | — | -0.16 | -2.75% | — | 0.00% | — | — | — | — | — |
| AIMD | Ainos, Inc. | $1.64 | 7.91M | +1,477% | -27% | — | +6,696% | -1.56 | 1.50 | 1120.96 | -3.32 | — | -2.82 | -153.73% | -66772.17% | -71702.26% | -74.38% | -53.08% | -49.00% | 0.77 | -22.45 | 1.10 | 0.98 | -0.86 | -5357.00% | -8302.00% | 2176.00% | -25.09% | -1.47 | -22.36% | 0.00% | 0.00% | 0.00% | -2.26 | -5.38 | 1512.06 | -3.08 |
| ARTL | Artelo Biosciences, Inc. | $1.19 | 2.75M | — | — | — | — | -0.09 | -0.92 | — | -0.10 | -0.03 | -0.35 | 0.00% | — | — | -1625.11% | 4102.16% | -343.49% | -0.54 | -58.78 | 0.17 | 0.15 | -0.01 | 31049.00% | — | 204.00% | -726.31% | -2.11 | 3064.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.15 | — | -46.19 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| GTBP | GT Biopharma, Inc. | $0.48 | 5.08M | — | — | — | — | -0.35 | -2.77 | — | -0.05 | -1.53 | -2.77 | 0.00% | — | — | -453.39% | 238.23% | -143.53% | 0.00 | — | 0.72 | 0.67 | 0.30 | 2305.00% | — | 4577.00% | -278.78% | -2.19 | 214.01% | 0.00% | 0.00% | 63.30% | -0.05 | -0.05 | — | -241.19 |
| PBM | Psyence Biomedical Ltd. | $2.54 | 48.31K | — | — | — | — | 121.05 | 18.22 | — | 113.47 | — | 18.22 | 0.00% | — | — | -47.61% | 1045.66% | 23.95% | 0.00 | -395.15 | 11.04 | 10.55 | -5.98 | -12268.00% | — | 2687.00% | -3.06% | -6.28 | 1068.81% | 0.00% | 0.00% | 12.94% | -31.76 | -31.07 | — | 112.16 |
| PTIX | Protagenic Therapeutics, … | $0.47 | 896.47K | — | — | — | — | -4.00 | 21.80 | — | -3.70 | — | 21.80 | 0.00% | — | — | -236.06% | 939.82% | -175.99% | 0.00 | — | 2.00 | 1.95 | 0.34 | -174.00% | — | 942.00% | -19.09% | -4.47 | 695.10% | 0.00% | 0.00% | 2.49% | -3.55 | -4.80 | — | -20.97 |
| REVB | Revelation Biosciences, I… | $1.32 | 1.95M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
| SLRX | Salarius Pharmaceuticals,… | $0.84 | 4.92M | — | — | — | — | -0.18 | 0.67 | — | 0.21 | 0.00 | 0.67 | 0.00% | — | — | -164.02% | 1120.04% | -116.05% | 0.15 | — | 1.98 | 1.61 | 0.40 | 15226842.00% | — | -6477.00% | -445.68% | -2.99 | 883.90% | 0.00% | 0.00% | 0.00% | 0.21 | 0.26 | — | -43.21 |
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.
- CEO
- Kraig T. Higginson
- Employees
- 2
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.02) − 1 = — (DCF, example).